VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics

BACKGROUND: A new class of antiretrovirals, AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs), has been proposed as a disease-modifying therapy to both reduce Human Immunodeficiency Virus Type 1 (HIV-1) RNA levels and the excessive immune activation now recognized as the major driver of not...

Descripción completa

Detalles Bibliográficos
Autores principales: Lori, Franco, De Forni, Davide, Katabira, Elly, Baev, Denis, Maserati, Renato, Calarota, Sandra A., Cahn, Pedro, Testori, Marco, Rakhmanova, Aza, Stevens, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477169/
https://www.ncbi.nlm.nih.gov/pubmed/23094055
http://dx.doi.org/10.1371/journal.pone.0047485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477169/
https://www.ncbi.nlm.nih.gov/pubmed/23094055
http://dx.doi.org/10.1371/journal.pone.0047485

Ejemplares similares